IP Library › Granted Patent US 12,318,635
Granted Patent B2
US 12,318,635 · App. 17/282,390 · Granted Jun 3, 2025

Apparatus and method for treating kidneys

Inventors: Benny Rousso (Rishon-LeZion, IL); Naama Winetraub (Holon, IL); Boaz Rippin (Beit Yehoshua, IL); Lior Eshel (Rishon-LeZion, IL); Assaf Erell (Ramat-Gan, IL); Rodny Zarini (Doar-Na Shimshon, IL)
Assignee: MDSG Innovation Ltd.
A61N7/00A61N2007/0004A61N2007/0078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,635
App. No.
17/282,390
Granted
Jun 3, 2025
Kind
B2
Abstract

The present invention relates to means and methods for modifying renal function in a subject, comprising selecting a patient requiring an increment in renal function; emitting a quantity of ultrasound radiation, enough to provide an increment in renal function, to at least one part of a kidney for a period of time from about 1 hours to about 30 days.

Claims (28)

1. A method for modifying renal function, comprising:

a. selecting a patient requiring an increment in renal function;

b. emitting a quantity of ultrasound radiation, enough to provide an increment in renal function, to at least one part of a kidney for a treatment period of time from about 1 hour to about 30 days;

c. monitoring temperature at skin or tissue, said monitoring is at multiple interface locations to manage ultrasound power distribution;

wherein said ultrasound radiation is characterized by having a pulse frequency from about 3 MHz to about 15 MHz and a duration from about 0.2 μsec to about 10 μsec; and

wherein said emitting comprises achieving renal function modification while avoiding inducing thermal adverse effects.

2. The method according to claim 1 , wherein said ultrasound radiation is characterized by individual emission pulses having an amplitude of less than 2 MPa.

3. The method according to claim 1 , wherein said ultrasound radiation is characterized by a pulse repetition rate from about 0.1 kHz to about 30 kHz.

4. The method according to claim 1 , wherein said emitting ultrasound radiation comprises emitting said ultrasound radiation between ribs.

5. The method according to claim 1 , wherein said emitting ultrasound radiation comprises emitting said ultrasound radiation over an area of skin.

6. The method according to claim 1 , further comprising positioning an ultrasound emission device in one or more locations selected from the group consisting of back, sides, under thorax and over thorax.

7. The method according to claim 1 , wherein said ultrasound radiation is characterized by having high frequency higher than 3 MHz and a duration from 0.2 μsec to 10 μsec.

8. The method according to claim 1 , further comprising achieving renal function modification while avoiding inducing cavitation adverse effects.

9. The method according to claim 1 , further comprising not using ultrasound contrast agent or any other injected material that, when exposed to ultrasonic radiations, a characteristic of said contrast agent or any other injected material is modified.

10. The method according to claim 1 , wherein said emitting is repeated for a period of time selected from the group consisting of at least a day, at least 3 days, at least a week, at least a month and at least 2 months.

11. The method according to claim 1 , wherein said emitting is applied intermittently for repetitive periods of time selected from a group consisting of: at least 5 minutes each, at least 10 minutes each, at least 15 minutes each and at least 20 minutes each.

12. The method according to claim 1 , wherein said emitting further comprises emitting for preventing acute kidney dysfunction.

13. The method according to claim 1 , wherein said emitting further comprises emitting for treating symptoms of heart failure in said patient.

14. The method according to claim 1 , wherein said emitting comprises not to cause cavitation in the tissue.

15. The method according to claim 1 , further comprising monitoring cavitation at skin or tissue, said monitoring is at multiple interface locations to manage ultrasound power distribution.

16. The method according to claim 1 , further comprising monitoring mechanical index at skin or tissue to be lower than 1.

17. A system for modifying renal function, comprising:

a. a plurality of transducer elements;

b. circuitry comprising instructions for:

i. emitting a quantity of ultrasound radiation, enough to provide an increment in renal function, to at least one part of a kidney for a treatment period of time from about 1 hour to about 30 days;

ii. monitoring temperature at skin or tissue, said monitoring is at multiple interface locations to manage ultrasound power distribution;

wherein said ultrasound radiation is characterized by having a pulse frequency from about 3 MHz to about 15 MHz and a duration from about 0.2 μsec to about 10 μsec; and

wherein said emitting comprises achieving renal function modification while avoiding inducing thermal adverse effects.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2021
From: ROUSSO, BENNY; WINETRAUB, NAAMA; RIPPIN, BOAZ; ESHEL, LIOR; ERELL, ASSAF; ZARINI, RODNY
To: MDSG INNOVATION LTD.
Reel/Frame 057012/0064 →
Continuity (2)
Provisional Application 62740535 · Oct 3, 2018
Related Publication 20210346725A1 · Nov 11, 2021
References Cited (47)
US 5558092A · Unger et al. · 1996 [cited by applicant]
US 6941172B2 · Nachum · 2005 [cited by applicant]
US 8382689B2 · Sliwa et al. · 2013 [cited by applicant]
US 8414494B2 · Vaezy et al. · 2013 [cited by applicant]
US 9072879B2 · Yang · 2015 [cited by applicant]
US 20020123702A1 · Cho · 2002 [cited by applicant]
US 20090112098A1 · Vaezy et al. · 2009 [cited by applicant]
US 20110092781A1 · Gertner · 2011 [cited by examiner]
US 20110208095A1 · Jolesz et al. · 2011 [cited by applicant]
US 20120010502A1 · Yang et al. · 2012 [cited by applicant]
US 20120065501A1 · Dae et al. · 2012 [cited by applicant]
US 20120215106A1 · Sverdlik et al. · 2012 [cited by applicant]
US 20150080926A1 · Emery · 2015 [cited by applicant]
US 20160038753A1 · Chornenky et al. · 2016 [cited by applicant]
US 20160059044A1 · Gertner · 2016 [cited by applicant]
US 20160113699A1 · Sverdlik et al. · 2016 [cited by applicant]
US 20160136462A1 · Lewis, Jr. et al. · 2016 [cited by applicant]
US 20160287909A1 · Maxwell · 2016 [cited by examiner]
US 20160332003A1 · Dae · 2016 [cited by examiner]
US 20170245874A1 · Bailey · 2017 [cited by examiner]
US 20180161002A1 · Alford et al. · 2018 [cited by applicant]
JP 2006192181 · 2006 [cited by applicant]
WO WO2018071908 · 2018 [cited by applicant]
WO WO2020070748 · 2020 [cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jun. 27, 2022 From the European Patent Office Re. Application No. 19869708.8. (10 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Jan. 4, 2022 From the Japan Patent Office Re. Application No. 2021-538486 and Its Translation Into English. (8 Pages). [cited by applicant]
Disposition of Dismissal of Procedure Dated Oct. 18, 2022 From the Japan Patent Office Re. Application No. 2021-538486 and Its Translation Into English. (8 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated Apr. 15, 2021 From the International Bureau of WIPO Re. Application No. PCT/IL2019/051085. (9 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Mar. 11, 2020 From the International Searching Authority Re. Application No. PCT/IL2019/051085. (15 Pages). [cited by applicant]
Invitation to Pay Additional Fees Dated Jan. 15, 2020 From the International Searching Authority Re. Application No. PCT/IL2019/051085. (2 Pages). [cited by applicant]
Fischer et al. “Renal Ultrafiltration Changes Induced by Focused US”, Radiology, 253(3): 697-705, Dec. 2009. [cited by applicant]
Gigliotti et al. “Ultrasound Modulates the Splenic Neurimmune Axis in Attenuating AKI”, Journal of the American Society of Nephrology, 26(10): 2470-2481, Published Online Feb. 2, 2015. [cited by applicant]
Gigliotti et al. “Ultrasound Prevents Renal Ischemia-Reperfusion Injury by Stimulating the Splenic Cholinergic Anti-Inflammatory Pathway”, Journal of the American Society of Nephrology, 24(9): 1451-1460, Published Onlin… [cited by applicant]
Hougardy et al. “Ultrasonic Stimulation of the Cholinergic Anti-Inflammatory Pathway for Renal Protection”, Journal of the American Society of Nephrology, 24(9): 1339-1341, Published Online Aug. 1, 2013. [cited by applicant]
Johns “Nonthermal Effects of Therapeutic Ultrasound: The Frequency Resonance Hypothesis”, Journal of Athletic Training, 37(3): 293-299, Jul.-Sep. 2002. [cited by applicant]
Kerschan-Schindl et al. “Whole-Body Vibration Exercise Leads to Alterations in Muscle Blood Volume”, Clinical Physiology, 21(3): 377-382, May 2001. [cited by applicant]
Koga et al. “Mild Electrical Stimulation and Heat Shock Ameliorates Progressive Proteinuria and Renal Inflammation in Mouse Model of Alport Syndrome”, Plos One, 7(8): 1c43852-1-c43852-11, Published Online Aug. 24, 2012. [cited by applicant]
Li et al. “Renal Interstitial Permeability Changes Induced by Microblubble-Enhanced Diagnostic Ultrasound”, Journal of Drug Targeting, 21(5): 507-514, Published Online Apr. 29, 2013. [cited by applicant]
Mcdannold et al. “Blood-Brain Barrier Disruption Induced by Focused Ultrasound and Circulating Preformed Microbubbles Appears to be Characterized by the Mechanical Index”, Ultrasound in Medicine and Biology, 34(5): 834-… [cited by applicant]
Mele et al. “Changing Paradigms in Cranio-Facial Regeneration: Current and New Strategies for the Activation of Endogenous Stem Cells”, Frontiers in Psychology, 7(62): 1-13, Published Online Feb. 24, 2016. [cited by applicant]
Miloradovic et al. “Vibroacustic Microvibrations enhance Kndney Blood Supply, Gloerular Filtration and Glutathione Peroxidase Activity in Spontaneously Hypertensive Rats”, General Physiology and Biophysics, 34(1): 89-94… [cited by applicant]
Sato ct al. “Low-Intensity Pulsed Ultrasound Rescues Insufficient Salivary Secretion in Autoimmune Sialadenitis”, Arthritis Research & Therapy, 17(1): 278-1-278-12, Published Online Oct. 7, 2015. [cited by applicant]
Singh et al. “Low-Frequency, Loe-Intensity Ultrasound as A Potential Novel Treatment for Type 2 Diabetes”, 2017 IEEE International Ultrasonic Symposium, IUS 2017, Washington, D.C., USA, Sep. 6-9, 2017, Abstract, Sep. 6,… [cited by applicant]
Varani et al. “Effect of Low Frequency Electromagnetic Fields on A2A Adenosine Receptors in Human Neutrophils”, British Journal of Pharmacology, 136(1): 57-66, May 2002. [cited by applicant]
Vincent et al. “Adenosine 2A Receptors in Acute Kidney Injury”, Acta Physiologica, 214(3): 303-310, Jul. 2015. [cited by applicant]
Yang et al. “Focused Ultrasound-Modulated Glomerular Ultrafiltration Assessed by Functional Changes in Renal Arteries”, Plos One, 8(1): e54034-1-e54034-6, Published Online Jan. 10, 2013. [cited by applicant]
Yang et al. “Low-Intensity Ultrasound-Induced Anti-Inflammatory Effects Are Mediated by Several New Mechanisms Including Gene Induction, Immunosuppressor Cell Promotion, and Enhancement of Exosome Biogenesis and Docking… [cited by applicant]
Cited By (1)
US 12,721,987